Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...

Shares of Allurion Technologies were trading higher in the after-hours market following ... studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ... balloon weight-loss product in combination with GLP-1 drugs. Allurion (NYSE:ALUR) announced about ten minutes ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual ... in its July 2024 offering to $6.00 per share after obtaining shareholder approval.

Unlike other approaches, Allurion’s balloon does not require surgery, endoscopy, or anaesthesia. After around four months, the balloon releases the liquid on its own and it passes out of the ...